Paolo Tarantino: Any agnostic approval should not stop efforts in biomarker discovery for ADCs

Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

“Of note, any agnostic approval should not stop efforts in biomarker discovery for ADCs. T-DXd works well for HER2 expressing (≥1+) breast cancer, but overexpression/amplification is required for GI tumors and mutations are the best predictors for NSCLC. Complexity is the norm, in oncology.

T-DXd granted Priority Review in the US for patients with metastatic HER2-positive (IHC 3+) solid tumors. One step closer to the first agnostic ADC, as well as the first agnostic HER2-targeted treatment.”

Read further.
Source: Paolo Tarantino/X